Oppenheimer Assumes Innoviva at Outperform, Announces Price Target of $35

Oppenheimer analyst Les Sulewski has initiated coverage of Innoviva (NASDAQ: INVA) with an 'Outperform' rating. The firm has set a price target of $35 for the company's stock.